RESUMEN
Hemopoiesis was studied in 88 patients with lung cancer during antitumor chemotherapy and its combination with a dry SB extract. Administration of the plant preparation was accompanied with hemopoiesis stimulation, intensification of bone-marrow erythro- and granulocytopoiesis and increase in the content of circulating precursors of the type of erythroid and granulomonocytic colony-forming units.
Asunto(s)
Protocolos de Quimioterapia Combinada Antineoplásica/efectos adversos , Carcinoma de Pulmón de Células no Pequeñas/tratamiento farmacológico , Carcinoma de Células Pequeñas/tratamiento farmacológico , Hematopoyesis/efectos de los fármacos , Neoplasias Pulmonares/tratamiento farmacológico , Plantas Medicinales , Adenocarcinoma/sangre , Adenocarcinoma/tratamiento farmacológico , Adulto , Anciano , Protocolos de Quimioterapia Combinada Antineoplásica/uso terapéutico , Carcinoma de Pulmón de Células no Pequeñas/sangre , Carcinoma de Células Pequeñas/sangre , Carcinoma de Células Escamosas/sangre , Carcinoma de Células Escamosas/tratamiento farmacológico , Ensayo de Unidades Formadoras de Colonias , Ciclofosfamida/administración & dosificación , Ciclofosfamida/efectos adversos , Doxorrubicina/administración & dosificación , Doxorrubicina/efectos adversos , Humanos , Neoplasias Pulmonares/sangre , Masculino , Metotrexato/administración & dosificación , Metotrexato/efectos adversos , Persona de Mediana Edad , Extractos Vegetales/uso terapéuticoRESUMEN
Cytostatic therapy of patients with lung cancer is attended with decrease in the relative number of T-lymphocytes and their theophylline-resistant population. Patients who were given SB showed a tendency towards increase of these parameters during antitumor chemotherapy. The immunoregulation index (IRI) in this case was approximately twice the background values during the whole period of investigation. The inclusion of SB in the therapeutic complex promotes increase in the number of immunoglobulins A at a stable level of immunoglobulins G.
Asunto(s)
Adyuvantes Inmunológicos/uso terapéutico , Protocolos de Quimioterapia Combinada Antineoplásica/efectos adversos , Neoplasias Pulmonares/tratamiento farmacológico , Plantas Medicinales , Adulto , Anciano , Protocolos de Quimioterapia Combinada Antineoplásica/uso terapéutico , Linfocitos B/efectos de los fármacos , Linfocitos B/inmunología , Ciclofosfamida/administración & dosificación , Ciclofosfamida/efectos adversos , Doxorrubicina/administración & dosificación , Doxorrubicina/efectos adversos , Endotoxinas , Humanos , Inmunoglobulina A/sangre , Inmunoglobulina G/sangre , Neoplasias Pulmonares/inmunología , Neoplasias Pulmonares/patología , Masculino , Metotrexato/administración & dosificación , Metotrexato/efectos adversos , Persona de Mediana Edad , Estadificación de Neoplasias , Linfocitos T/efectos de los fármacos , Linfocitos T/inmunologíaRESUMEN
The paper outlines the principles in designing hemostimulators by using glycosamineglycans. Hemostimulating properties of the tested agents is likely to be primarily due to the presence of D-glucuronic acid in their structure. The homotypic mechanisms are largely responsible for all agents' effect in stimulating hemopoiesis. Thus, they all virtually activate the function of the hemopoiesis-inducing microenvironment. In addition, they directly or indirectly stimulate the processes of proliferation and differentiation of precursor cells of erythro- and granulomonocytopoiesis.